"Researchers are making progress toward understanding how some cases of glaucoma begin. A new study from the National Eye Institute reveals that myocilin—a protein linked to a significant fraction of glaucoma—is needed to insulate peri"...
(Generic versions may still be available.)
Vitravene Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Vitravene (fomivirsen) Injection is an antiviral drug used for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), who are intolerant of or have a contraindication to other treatment(s) for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis. The brand name Vitravene is discontinued, but generic versions may be available. Common side effects of Vitravene Injection include:
- eye inflammation (uveitis) including iritis and vitritis
- abnormal vision
- blurred vision
- eye pain
- eye sensitivity to light
- retinal detachment
- abdominal pain
- low levels of iron in the blood (anemia)
- systemic CMV, and
The recommended dose of Vitravene is 330 µg (0.05 mL). Vitravene may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Vitravene should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Vitravene (fomivirsen) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Vitravene FDA Prescribing Information: Side Effects
The most frequently observed adverse experiences have been cases of ocular inflammation (uveitis) including iritis and vitritis. Ocular inflammation has been reported to occur in approximately 1 in 4 patients. Inflammatory reactions are more common during induction dosing. Delaying additional treatment with Vitravene (fomivirsen) † and the use of topical corticosteroids have been useful in the medical management of inflammatory changes (SEE PRECAUTIONS, General).
Adverse experiences reported in approximately 5 to 20% of patients have included:
Ocular: abnormal vision, anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, decreased visual acuity, desaturation of color vision, eye pain, floaters, increased intraocular pressure, photophobia, retinal detachment, retinal edema, retinal hemorrhage, retinal pigment changes, uveitis, vitritis.
Adverse experiences reported in approximately 2 to 5% of patients have included:
Ocular: application site reaction, conjunctival hyperemia, conjunctivitis, corneal edema, decreased peripheral vision, eye irritation, hypotony, keratic precipitates, optic neuritis, photopsia, retinal vascular disease, visual field defect,vitreous hemorrhage, vitreous opacity.
Systemic: abnormal liver function, abnormal thinking, allergic reactions, anorexia, back pain, bronchitis, cachexia, catheter infection, chest pain, decreased weight, dehydration, depression, dizziness, dyspnea, flu syndrome, increased cough, increased GGTP, kidney failure, lymphoma like reaction, neuropathy, neutropenia, oral monilia, pain, pancreatitis, sweating, thrombocytopenia.
Read the entire FDA prescribing information for Vitravene (Fomivirsen)
Additional Vitravene Information
Report Problems to the Food and Drug Administration
Get breaking medical news.